European Pharmaceutical Review

NOVEMBER 24, 2022

Tackling pharmaceutical counterfeiting continues, therefore, to be a clear and present priority for manufacturers, healthcare authorities and law enforcement. One area in which the problem can be tackled effectively is product packaging. Quality assurances through the use of holograms.

Pharmaceutical 111

Pharmaceutical Manufacturing Pharmaceutical products Distribution 111

European Pharmaceutical Review

FEBRUARY 12, 2024

‘From bench to bedside’ is a well-known aphorism that merely hints at the arduous journey drug treatments must undergo from their position as a candidate molecule or soon to be explored pathway, to becoming a tablet, injection, or infusion administered to patients worldwide. How does it do this?

Manufacturing 98

Manufacturing Medicine Leads Patients 98

PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. billion in 2021 to $9.23

Marketing 98

Marketing Pharma Healthcare Healthcare 98

Pharmaceutical Technology

JULY 26, 2022

The SPAC is sponsored by a Frazier Healthcare Partners affiliate. Through an oversubscribed and upsized private investment in public equity (PIPE) led jointly by Frazier Healthcare Partners and Bain Capital Life Sciences, the combined business is expected to receive nearly $235m and funds held in the trust account of FLAC.

Pharma 59

Pharma Specialization Healthcare Healthcare 59

European Pharmaceutical Review

NOVEMBER 12, 2024

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 The expansion is set to strengthen AstraZeneca’s capability to manufacture biologic medicines for patients worldwide. billion of capital investment in the US.

Manufacturing 59

Manufacturing Biopharma Healthcare Healthcare 59

Clarify Health

APRIL 26, 2022

Artificial intelligence (AI) has the potential to affect healthcare in profound ways — propelling better data-driven decisions on diagnoses, treatments, and population health management. health system realize $150 billion in savings by 2026. During the panel, Dr. Ramadoss gave examples of AI applications in healthcare.

Healthcare 52

Healthcare Healthcare Management Media 52

Penrod

APRIL 1, 2024

What CMS-0057-F Means for Health Insurance Companies In January 2024, CMS finalized its interoperability and prior authorization rule that requires various healthcare insurance entities to abide by the latest electronic health information exchange and prior authorization process for clinical services.

Electronics 52

Electronics Insurance Healthcare Healthcare 52

European Pharmaceutical Review

SEPTEMBER 26, 2023

Multiple sclerosis is a chronic condition with no cure at present and timely access to affordable, high-quality healthcare is therefore even more essential.” This was in addition to Phase I PK/PD study results and a confirmatory Phase III Antelope study in RRMS patients. The site is planned to be completed by 2026.

Food and Drug Administration 59

Food and Drug Administration Medicine Distribution Food 59

Pharmaceutical Technology

OCTOBER 14, 2022

ELVN-001 is a selective small-molecule BCR-ABL inhibitor designed to treat chronic myeloid leukaemia patients. This cash will be used to advance Enliven’s pipeline of candidates through multiple clinical milestones while providing runway into early 2026. Enliven is currently advancing two product candidates, ELVN-001 and ELVN-002.

Management 52

Management Pharmaceutical Healthcare Healthcare 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. starting new lung cancer patients on LIBTAYO® or melanoma patients on Opdualag instead of KEYTRUDA®).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Infuse Medical

JULY 4, 2024

VR in healthcare is doing magic by transforming the conventional working environment to the next level. Brief Overview of the Importance of Medical Device Maintenance Medical device maintenance ensures patient safety, operational efficiency, and regulatory compliance in healthcare settings. What is VR Training?

Training 52

Training Medical Healthcare Healthcare 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. Insurance approval and distribution for specialty drugs can cause significant treatment delays up to three to four weeks for many patients.

Prescription 52

Prescription Medical Patients Distribution 52

pharmaphorum

JULY 26, 2022

The Dutch biotech will book around $235 million from a private placement led by Frazier Healthcare Partners and Bain Capital Life Sciences and funds held in Frazier’s trust account.

Side effects 52

Side effects Safety Pharma Patients 52

PM360

APRIL 7, 2023

Most immediately, it will add confusion in the healthcare space,” explains Daniel Sontupe, Associate Partner, Managing Director, The Bloc Value Builders. This will create confusion in the marketplace and may possibly lead to delivery of misinformation to healthcare providers (HCPs) regarding a brand’s drug coverage,” Bambalas says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. That impacts launches most.

Doctors 59

Doctors Medicine Marketing Sales 59

Clarify Health

MAY 4, 2022

Population health management is best supported by a data-driven approach with a structured analytics process driven by skilled and competent healthcare leaders and clinicians. Reports estimate that the healthcare analytics market size is expected to grow to $75.1 billion by 2026.

Management 52

Management Healthcare Healthcare Training 52

Clarify Health

MAY 4, 2022

Population health management is best supported by a data-driven approach with a structured analytics process driven by skilled and competent healthcare leaders and clinicians. Reports estimate that the healthcare analytics market size is expected to grow to $75.1 billion by 2026.

Management 52

Management Healthcare Healthcare Training 52

Medico Reach

MARCH 24, 2023

As a result, a global approach to healthcare has emerged continually over the years. Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. To address the shortcomings of existing treatments, routine utilization of patient data becomes crucial. billion in 2021.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

As a result, a global approach to healthcare has emerged continually over the years. Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. To address the shortcomings of existing treatments, routine utilization of patient data becomes crucial. billion in 2021.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

PM360

FEBRUARY 1, 2024

Confidence Amidst Funding Challenges The resilience and confidence observed amidst funding challenges within the biotech sector represent a testament to the industry’s steadfast commitment to innovation and transformative advancements in healthcare. Addressing these challenges necessitates a multifaceted approach.

Recruitment 52

Recruitment Healthcare Healthcare Management 52

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. Accelerated approvals are really important to society and patient populations, and industry,” Califf told the JP Morgan Conference. “[But]

FDA 52

FDA Prescription Medicine Biopharma 52

Clarivate

AUGUST 27, 2024

In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients. Abbott’s Volt should join the party in early 2026. Still, analysts and providers project that Farapulse, which has more than 70% of the global market today, will continue to dominate at least through 2025.

Marketing 52

Marketing Competition FDA Electronics 52

European Pharmaceutical Review

FEBRUARY 7, 2023

In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. Edward Turtle is a products lawyer, regulatory advisor and litigator with particular experience in the healthcare, technology and consumer product sectors. of the MDR and Article 110.4

Medical 117

Medical Government Marketing Medicine 117

Evolve Your Success

JANUARY 24, 2023

If you’re someone that’s trying to get into medical sales, maybe it’s pharmaceutical, medical device, or any kind of healthcare sales, then you better be tuning in to this episode. I loved my job and my patients. Also, COVID changed so much with patient interaction. They’re healthcare sales reps.

Medical sales 52

Medical sales Sales Medical Education 52

pharmaphorum

DECEMBER 14, 2022

As many strive to bring about transformation in healthcare, Angelini Ventures takes a new approach to investments in digital health and life sciences companies that drive healthcare innovation and improve patient experiences. Introducing Angelini Ventures. Improving mental health treatment access in Italy.

Healthcare 105

Healthcare Healthcare Patients Management 105

European Pharmaceutical Review

AUGUST 19, 2022

billion by 2026. In addition, investigators cited the increasing geriatric patient population, growing consumption of medicines, rising healthcare expenditure, improving healthcare infrastructure in emerging markets and mounting pressure to reduce healthcare costs as other factors driving market growth. percent, 4.1

Manufacturing 98

Manufacturing Marketing Pharma Healthcare 98

PM360

SEPTEMBER 28, 2022

healthcare system with major implications for the Medicare Advantage and Medicare Part D programs. Patient behavior on insulin: Part D plans will have limited opportunity to adjust strategy for 2023, given bids are locked in. Behavioral response (patient adherence/persistence) to a lower out-of-pocket cost for insulin is unknown.

Government 97

Government Manufacturing Prescription Marketing 97

pharmaphorum

JANUARY 17, 2023

” The combination has the potential to deliver higher accuracy in assisting with the diagnosis of a disease in a healthcare setting, or monitoring progression for a clinical trial, according to a statement on the transaction. million) to its top-line in 2023 with “considerable growth” next year.

Marketing 105

Marketing Healthcare Healthcare Patients 105

pharmaphorum

JANUARY 4, 2023

Often referred to as “off-the-shelf,” allogeneic cell therapies are derived from a single source of donor cells, cultured, and expanded, and then used to treat many patients. A single large batch of engineered cells can potentially treat hundreds of patients. The approval represents a significant moment for the CGT industry.

Transportation 98

Transportation Manufacturing Patients Networking 98

Clarify Health

FEBRUARY 6, 2024

Prior Authorization While an important tool for health plans to control costs and prevent fraud, waste, and abuse, the prior authorization process is burdensome for providers, health plans, and patients. CMS took action recently to address common pain points for all parties. The rule had a phased implementation approach.

Networking 52

Networking Insurance Government Management 52

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

World of DTC Marketing

JULY 28, 2022

Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. This would include drugs covered by both Medicare Part B (physician-administered drugs) and Part D (prescription medications).

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

Clarivate

OCTOBER 17, 2024

Healthcare delivery has not been the hottest topic on the campaign trail this election season, despite sharp policy differences between the candidates and parties. These prior actions align with the Biden Administration’s policy of strict antitrust enforcement, particularly concerning healthcare. During the Sept.

Healthcare 52

Healthcare Healthcare Government Insurance 52